AI Summary
Tempus AI has agreed to acquire Personalis in a $1.7 billion deal to strengthen its precision oncology capabilities. The combined company will leverage AI and genomic sequencing technologies to advance personalized cancer treatment and diagnosis.
This article first appeared on GuruFocus.Tempus AI (NASDAQ:TEM), a Chicago-based healthcare technology company using artificial intelligence for tailored disease prevention and treatment, has agreed to acquire Personalis (NASDAQ:PSNL), a California-based cancer-testing company, in a…
Full story reconstructed from Biztoc.com. Formatting and media may differ from the original.
View original at Biztoc.com